SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is capturing community attention as the project emphasizes long-term culture building, organic growth, and its alignment with cannabis advocacy ahead of 4/20. Participants are actively debating the token's potential for real-world integration in the cannabis space while closely monitoring community-led initiatives and social engagement.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is facing extreme volatility and intense community backlash after a massive, rapid price rally was followed by a sharp collapse, leading to widespread accusations of an insider-led rug pull. While some traders are actively seeking short-term gains through dead cat bounces and technical setups, many community members are warning of a scam due to the highly concentrated token supply and ongoing investigations into potential market manipulation.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging as a legacy project with deep roots in early internet culture, drawing significant attention for its historical status as the original crypto satire from 2011. The community is heavily focused on its long-standing lore, verifiable origins, and recent on-chain presence, with many investors viewing its unique narrative as a differentiator in the crowded memecoin market.

Asteroid Shiba is inspired by a real-life event where a Shiba Inu plush toy named "Asteroid" served as a zero-gravity indicator during the Polaris Dawn mission. This connection to space travel gives it a narrative that's both whimsical and grounded in a tangible event, differentiating it from other meme coins which might rely solely on internet culture or celebrity endorsements.  The coin's mascot, the zero-gravity Shiba Inu, was designed by a young cancer survivor, Liv Perrotto, adding a layer of emotional connection and human interest story that's rare in the crypto space. This backstory not only provides a unique selling point but also a community rallying point.

Asteroid Shiba

Asteroid Shiba is generating significant buzz as a high-volatility memecoin following a rapid price surge, sparking intense debate among community members over whether it represents a sustainable growth opportunity or a speculative pump-and-dump cycle. While many traders are celebrating aggressive gains and comparing it to other viral tokens, others remain cautious, questioning the legitimacy of its rapid movement and advising others to lock in profits.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors weigh a critical BlueBird 7 satellite launch against a structured share sale by major stakeholder Rakuten. While community sentiment is heavily focused on the potential for a short squeeze and long-term constellation deployment, discussions are currently dominated by debates over launch cadence, the impact of the equity offering, and the company's ability to scale manufacturing to meet future targets.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is experiencing significant market interest driven by institutional developments, including its inclusion in upcoming CME futures and active adoption across various DeFi and gaming protocols. Community sentiment is notably polarized, with many investors aggressively accumulating during dips and citing long-term potential, while others express caution regarding price volatility and project comparisons.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending as investors react to a recent corporate rebranding and executive shifts while monitoring clinical progress for its MDD and GAD treatment pipeline. Community sentiment is polarized, with some traders optimistic about the potential for regulatory tailwinds and upcoming trial data, while others remain skeptical due to the company's history of dilution and previous share price performance.

Maulcoin

Maulcoin is trending as a highly active community of "Maulers" continues to push the project, focusing on the development led by a transparent math teacher. The group is actively engaging on social platforms, discussing the potential for weekend momentum and the unique, cult-like branding that has fueled ongoing interest in the token.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant buzz as the community actively rallies behind its humorous branding and ongoing engagement efforts, including poker events and social media campaigns. Investors are debating its long-term potential while the community remains highly vocal about the project's staying power and retail-driven mission.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community highlights the launch of its Data Marketplace, which facilitates the integration of institutional-grade financial data from major entities like Fidelity and Tradeweb into decentralized ecosystems. Investors are actively discussing the protocol's utility in the Real World Asset (RWA) space, its U.S. government partnerships, and its revenue-sharing model through token buybacks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ESSA Announces Completion of Arrangement with XenoTherapeutics

ESSA Announces Completion of Arrangement with XenoTherapeutics ESSA Announces Completion of Arrangement with XenoTherapeutics PR Newswire SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada...

Shares of Essa Pharma, Inc. (<a class="mention" data-mention="$EPIX" data-symbol-id="EPIX" href="https://stocktwits.com/symbol/EPIX" target="_blank">$EPIX</a>) plummeted 70% on Friday morning after the company announced it would end its Phase 2 study of masofaniten, its lead drug candidate for prostate cancer.&nbsp;Essa’s decision follows an interim analysis indicating that the study was unlikely to meet its primary endpoint, a move aimed at prioritizing patient benefit and safety.&nbsp;CEO David Parkinson noted that the trial’s emerging efficacy profile for masofaniten, when combined with enzalutamide, was insufficient to justify continuation.Richard Glickman, Chairman of Essa’s Board, confirmed that the company is shifting focus to preserve capital, initiating a strategic review to explore options for maximizing shareholder value.&nbsp;JonesResearch analyst Soumit Roy downgraded Essa Pharma to ‘Hold’ from ‘Buy,’ saying “we were wrong in our assessment of masofaniten's potential.”&nbsp;Roy also anticipates the stock to trade at a 40%-50% discount to its cash per share, currently $2.64, until further guidance from management.<figure class="image"><a href="https://stocktwits.com/symbol/EPIX"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_01_at_9_42_09_AM_25b012ad7e.png" alt="Screenshot 2024-11-01 at 9.42.09 AM.png" width="1314" height="320"></a><figcaption>EPIX sentiment and message volume on Nov. 1 as of 9:45 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment turned ‘extremely bearish’ (9/100), the lowest in a year, with several users questioning the company’s pipeline viability.&nbsp;Some predicted a continued slide, with expectations of the stock trading below $1 as large shareholders exit their positions for tax write-offs.<stembedurl>https://stocktwits.com/StarLord13/message/590874905</stembedurl><stembedurl>https://stocktwits.com/elmono/message/590874567</stembedurl>Essa’s stock is down about 20% year-to-date as of Thursday’s close.&nbsp;Shares of the company are currently trading at their lowest level in over two years.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/wayfair-stock-rises-on-q3-earnings-beat/cJEYA3ARBk">Wayfair Thrills Retail Crowd As Stock Soars Premarket On Big Q3 Earnings Beat</a>

Shares of Essa Pharma are currently trading at their lowest level in over two years.

Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade

Richard Glickman, Chairman of Essa’s Board, confirmed that the company is shifting focus to preserve capital, initiating a strategic review

Equity

Richard Glickman, Chairman of Essa’s Board, confirmed that the company is shifting focus to preserve capital, initiating a strategic review


ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

EPIX
Essa Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EPIX News

EPIXEssa Pharma Inc